These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 31333843)

  • 1. Understanding the neural mechanisms of lisdexamfetamine dimesylate (LDX) pharmacotherapy in Binge Eating Disorder (BED): a study protocol.
    Griffiths KR; Yang J; Touyz SW; Hay PJ; Clarke SD; Korgaonkar MS; Gomes L; Anderson G; Foster S; Kohn MR
    J Eat Disord; 2019; 7():23. PubMed ID: 31333843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring bi-directional impacts of Lisdexamfetamine dimesylate on psychological comorbidities and quality of life in people with Binge Eating Disorder.
    Griffiths KR; Boulet S; Barakat S; Touyz S; Hay P; Maguire S; Kohn MR
    J Eat Disord; 2024 Jun; 12(1):80. PubMed ID: 38872181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lisdexamfetamine for binge eating disorder in adults: a systematic review of the efficacy and safety profile for this newly approved indication - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2015 Apr; 69(4):410-21. PubMed ID: 25752762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional Connectivity Mechanisms Underlying Symptom Reduction Following Lisdexamfetamine Treatment in Binge-Eating Disorder: A Clinical Trial.
    Griffiths KR; Breukelaar IA; Harvie G; Yang J; Foster SL; Harris AW; Clarke S; Hay PJ; Touyz S; Korgaonkar MS; Kohn MR
    Biol Psychiatry Glob Open Sci; 2024 Jan; 4(1):317-325. PubMed ID: 38298797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time course of the effects of lisdexamfetamine dimesylate in two phase 3, randomized, double-blind, placebo-controlled trials in adults with binge-eating disorder.
    McElroy SL; Hudson JI; Gasior M; Herman BK; Radewonuk J; Wilfley D; Busner J
    Int J Eat Disord; 2017 Aug; 50(8):884-892. PubMed ID: 28481434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary outcomes and qualitative findings of an open-label feasibility trial of lisdexamfetamine dimesylate for adults with bulimia nervosa.
    Dixon L; Bartel S; Brown V; Ali SI; Gamberg S; Murphy A; Brewer KL; McElroy SL; Kaplan A; Nunes A; Keshen AR
    J Eat Disord; 2023 May; 11(1):81. PubMed ID: 37218020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lisdexamfetamine Dimesylate for Adults with Moderate to Severe Binge Eating Disorder: Results of Two Pivotal Phase 3 Randomized Controlled Trials.
    McElroy SL; Hudson J; Ferreira-Cornwell MC; Radewonuk J; Whitaker T; Gasior M
    Neuropsychopharmacology; 2016 Apr; 41(5):1251-60. PubMed ID: 26346638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of lisdexamfetamine dimesylate on eating behaviour and homeostatic, reward and cognitive processes in women with binge-eating symptoms: an experimental medicine study.
    Schneider E; Martin E; Rotshtein P; Qureshi KL; Chamberlain SR; Spetter MS; Dourish CT; Higgs S
    Transl Psychiatry; 2022 Jan; 12(1):9. PubMed ID: 35013131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impulsivity and Its Relationship With Lisdexamfetamine Dimesylate Treatment in Binge Eating Disorder.
    Griffiths KR; Aparício L; Braund TA; Yang J; Harvie G; Harris A; Hay PJ; Touyz S; Kohn MR
    Front Psychol; 2021; 12():716010. PubMed ID: 34531798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lisdexamfetamine and binge-eating disorder: A systematic review and meta-analysis of the preclinical and clinical data with a focus on mechanism of drug action in treating the disorder.
    Schneider E; Higgs S; Dourish CT
    Eur Neuropsychopharmacol; 2021 Dec; 53():49-78. PubMed ID: 34461386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Characteristics and Treatment Response to Lisdexamfetamine Dimesylate Versus Placebo in Adults With Binge Eating Disorder: Analysis by Gender and Age.
    Kornstein SG; Bliss C; Kando J; Madhoo M
    J Clin Psychiatry; 2019 Feb; 80(2):. PubMed ID: 30817099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lisdexamfetamine dimesylate in binge eating disorder: a placebo controlled trial.
    Guerdjikova AI; Mori N; Blom TJ; Keck PE; Williams SL; Welge JA; McElroy SL
    Hum Psychopharmacol; 2016 Sep; 31(5):382-91. PubMed ID: 27650406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lisdexamfetamine Dimesylate Effects on Binge Eating Behaviour and Obsessive-Compulsive and Impulsive Features in Adults with Binge Eating Disorder.
    McElroy SL; Mitchell JE; Wilfley D; Gasior M; Ferreira-Cornwell MC; McKay M; Wang J; Whitaker T; Hudson JI
    Eur Eat Disord Rev; 2016 May; 24(3):223-31. PubMed ID: 26621156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lisdexamfetamine maintenance treatment for binge-eating disorder following successful treatments: randomized double-blind placebo-controlled trial.
    Grilo CM; Ivezaj V; Yurkow S; Tek C; Wiedemann AA; Gueorguieva R
    Psychol Med; 2024 Sep; 54(12):1-11. PubMed ID: 39258475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationships between clinical scales and binge eating days in adults with moderate to severe binge eating disorder in two Phase III studies.
    Citrome L; Kando JC; Bliss C
    Neuropsychiatr Dis Treat; 2018; 14():537-546. PubMed ID: 29497297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of lisdexamfetamine on emotional network brain dysfunction in binge eating disorder.
    Fleck DE; Eliassen JC; Guerdjikova AI; Mori N; Williams S; Blom TJ; Beckwith T; Tallman MJ; Adler CM; DelBello MP; Strakowski SM; McElroy SL
    Psychiatry Res Neuroimaging; 2019 Apr; 286():53-59. PubMed ID: 30903953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase 3, Multicenter, Open-Label, 12-Month Extension Safety and Tolerability Trial of Lisdexamfetamine Dimesylate in Adults With Binge Eating Disorder.
    Gasior M; Hudson J; Quintero J; Ferreira-Cornwell MC; Radewonuk J; McElroy SL
    J Clin Psychopharmacol; 2017 Jun; 37(3):315-322. PubMed ID: 28383364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Cost Effectiveness of Lisdexamfetamine Dimesylate for the Treatment of Binge Eating Disorder in the USA.
    Ágh T; Pawaskar M; Nagy B; Lachaine J; Vokó Z
    Clin Drug Investig; 2016 Apr; 36(4):305-12. PubMed ID: 26914658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Efficient Combination Therapy with Lisdexamfetamine Dimesylate and Topiramate in Improving Binge Eating Scale & Metabolic Profile in Binge Eating Disorder: A Randomized Control Trial.
    Mokhtari F; Taghavi M; Mashayekh M
    Clin Psychopharmacol Neurosci; 2024 Aug; 22(3):493-501. PubMed ID: 39069689
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.